TBC1 domain family member 10AGenealiases: EPI64 · TBC1D10 · dJ130H16.1 · dJ130H16.2
Q-omics provides the consensus-scored TBC1D10A profile across patient tissues and cancer cell-line models. TBC1D10A expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TBC1D10A is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TBC1D10A RNA expression shows 19,440 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, COAD, and ACC as cancer lineages where TBC1D10A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D10A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D10A survival associations across molecular data types. TBC1D10A RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D10A RNA expression–survival associations across cancer types. High TBC1D10A expression shows unfavorable associations in UVM and ACC, but favorable associations in ESCA, LGG, CHOL and THCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TBC1D10A RNA expression.
This table summarizes TBC1D10A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D10A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D10A shows lower tumor expression in COAD, KICH, KIRP and READ and higher tumor expression in LIHC and CHOL. The COAD box plot shows higher TBC1D10A RNA expression in normal versus tumor tissue (log2 FC = −0.545, t-test p < 0.001).
This table shows molecular features associated with TBC1D10A in patient tissues and cancer cell lines. In patient samples, TBC1D10A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D10A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
